VR Logo

Immunovant Inc. (IMVT) download report


Healthcare | Biotechnology & Pharma Research

Immunovant Inc. (IMVT) Premium Coverage

53 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases.

IPO Date: 21-Jun-2019

Exec. Chairperson of the Board: Dr. Frank M. Torti M.B.A., M.D., MBA

CEO & Director: Dr. Peter Salzmann M.B.A., M.D.

Listing: NASDAQ: IMVT

Country: United States

Headquarters: New York, NY

Website: https://immunovant.com

Key Facts

Market cap: $473.01 Mln

Revenue (TTM): $0.00 Mln

Earnings (TTM): $-156.73 Mln

Cash: $493.82 Mln

Total Debt: $2.36 Mln

Insider's Holding: 64.61%

Liquidity: Low

52 Week range: $3.15 - 11.37

Shares outstanding: 116,505,000

5 Years Aggregate:

  • CFO: $-399.64 Mln
  • EBITDA: $-330.06 Mln
  • Net Profit: $-467.29 Mln

Stock Performance

Time Period Immunovant (IMVT) S&P BSE Sensex S&P Small-Cap 600
YTD-53.29-9.18-18.78
1 month-5.69-4.78-8.00
3 months-27.77-9.66-13.65
1 Year-62.350.81-17.19
3 Years-25.9510.336.10
5 Years--11.345.87
10 Years--11.749.84
As on 01-Jul-2022
Year Immunovant (IMVT) S&P Small-Cap 600 S&P BSE Sensex
2021-81.5525.2721.99
2020191.059.5715.75